Radiosensitivity in breast cancer assessed by the Comet and micronucleus assays by Djuzenova, C S et al.
Radiosensitivity in breast cancer assessed by the Comet and
micronucleus assays
CS Djuzenova*,1,BM u ¨hl
1, M Fehn
1, U Oppitz
1,BM u ¨ller
1 and M Flentje
1
1Klinik fu ¨r Strahlentherapie der Universita ¨t Wu ¨rzburg, Josef-Schneider-Str. 11, Wu ¨rzburg D-97080, Germany
Spontaneous and radiation-induced genetic instability of peripheral blood mononuclear cells derived from unselected breast cancer
(BC) patients (n¼50) was examined using the single-cell gel electrophoresis (Comet) assay and a modified G2 micronucleus (MN)
test. Cells from apparently healthy donors (n¼16) and from cancer patients (n¼9) with an adverse early skin reaction to
radiotherapy (RT) served as references. Nonirradiated cells from the three tested groups exhibited similar baseline levels of DNA
fragmentation assessed by the Comet assay. Likewise, the Comet analysis of in vitro irradiated (5Gy) cells did not reveal any significant
differences among the three groups with respect to the initial and residual DNA fragmentation, as well as the DNA repair kinetics.
The G2 MN test showed that cells from cancer patients with an adverse skin reaction to RT displayed increased frequencies of both
spontaneous and radiation-induced MN compared to healthy control or the group of unselected BC patients. Two patients from the
latter group developed an increased early skin reaction to RT, which was associated with an increased initial DNA fragmentation in
vitro only in one of them. Cells from the other BC patient exhibited a striking slope in the dose–response curve detected by the G2
MN test. We also found that previous RT strongly increased both spontaneous and in vitro radiation-induced MN levels, and to a
lesser extent, the radiation-induced DNA damage assessed by the Comet assay. These data suggest that clinical radiation may
provoke genetic instability and/or induce persistent DNA damage in normal cells of cancer patients, thus leading to increased levels of
MN induction and DNA fragmentation after irradiation in vitro. Therefore, care has to be taken when blood samples collected
postradiotherapeutically are used to assess the radiosensitivity of cancer patients.
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Breast cancer (BC) is the common type of malignancy in females,
accounting for approximately 21% of all cancer cases in women
worldwide (Parkin et al, 1999). Out of all BC patients, 2% have a
strong genetic predisposition, caused by the highly penetrant
BRCA1 and BRCA2 genes (Peto et al, 1999). Because these genes
cannot account for the overall increased risk in the relatives of BC
cases (Baeyens et al, 2002), it was suggested that a substantial
proportion of BC patients may be predisposed to cancer through
mutations in low penetrance genes (Teare et al, 1994; Roberts et al,
1999; Scott et al, 1999; Scott, 2004), which may be genes involved
in DNA damage processing and repair.
Several DNA damage processing and repair pathways constitute
a guard system that protects cells against genetic instability
and tumorigenesis. Both genetic instability and impaired DNA
restitution have been pointed out as factors underlying increased
susceptibility to malignancy (for reviews, see Lengauer et al,
1998; Thompson and Schild, 2002). The biological importance
of genetic instability and DNA repair mechanisms in cancer
development is particularly well illustrated by the autosomal
recessive disorders ataxia telangiectasia, Fanconi anaemia and
Nijmegen breakage syndrome. These chromosome breakage
syndromes are characterised by various defects in DNA repair,
predisposition to different forms of malignancy and increased
radiosensitivity (for a review, see Carney 1999). Apart from
these rare syndromes, the deficient DNA repair capacity has
been proposed to be a predisposing factor in familial BC and
in some sporadic BC cases (Parshad et al, 1996). Genomic
instability has also been described for various hereditary
cancers including hereditary BC (Rothfuß et al, 2000; Baeyens
et al, 2002).
Genomic instability and DNA repair capacity have been
analysed in numerous population-based studies using a variety
of assays that assess chromosomal aberrations, sister chromatid
exchanges, micronuclei (MN), DNA fragmentation by means of the
Comet assay, etc. Some of these studies have revealed reduced
DNA repair capacity in peripheral blood mononuclear cells
(PBMCs, exposed in vitro to ionising radiation (IR) or UV) from
BC patients, as evaluated by the chromosome aberration assay
(Rigaud et al, 1990; Helzlsouer et al, 1995; Parshad et al, 1996) as
well as by the MN test (Scott et al, 1998, 1999; Baeyens et al, 2002).
Furthermore, a series of studies have found elevated G2
chromosomal radiosensitivity in the blood cells from BC patients
(Baria et al, 2001; Riches et al, 2001; Baeyens et al, 2002).
Interestingly, there has been no correlation between the G2
chromosome aberration and G0 MN assays performed simulta-
neously on cells from 80 patients, which were either G2 (38%) or
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sG0 (21%) sensitive, with only 4% sensitive in both assays (Scott
et al, 1999). Prompted by the finding that the G2 chromosome
aberration test yields a larger portion of sensitive patients than the
G0 MN test (Scott et al, 1999) and by the potency of the G2
metaphase test in assessing cytogenetic responses (Parshad et al,
1996; Baria et al, 2001; Riches et al, 2001; Baeyens et al, 2002), we
applied here a modified G2 MN test. Unlike the conventional G0
MN test, our method involved cells stimulated with phytohema-
gglutinin (PHA) for 48h prior to irradiation, as commonly used for
assessing G2 chromosomal aberrations (Scott et al, 1998).
Another convenient test to evaluate both genetic instability and
DNA repair capacity is the single-cell gel electrophoresis or Comet
assay (Singh et al, 1988; Olive et al, 1990). We have shown recently
that this method allows the discrimination of carriers of chromo-
some instability syndromes including ataxia telangiectasia and
Fanconi anaemia (Djuzenova et al, 1999, 2001). In addition, using
the Comet assay, we have found the background and induced DNA
damage in the peripheral blood lymphocytes from BC patients to be
similar to that in control individuals (Djuzenova et al, 1999).
Consistent with these data, nonirradiated lymphocytes from patients
with multiple tumours (Mu ¨ller-Vogt et al, 2003), lung cancer
(Rajaee-Behbahani et al, 2001) and BC (Alapetite et al, 1999) have
also been reported to exhibit the same range of DNA damage as
control cells. Similarly, no difference has been revealed by the Comet
assay between cells from control subjects and patients with BRCA1
mutation, after irradiation with 2Gy in vitro (Rothfuß et al, 2000).
In contrast to the above findings, increased basal as well as
elevated radiation- and doxorubicin-induced DNA damage levels
have been observed in the blood lymphocytes from BC patients
(Blasiak et al, 2004; Colleu-Durel et al, 2004; Hussien et al, 2005).
Despite extensive studies into the relationship between cellular
radiation tests, cancer risk and clinical radiation reaction, a
convincing opinion has not been formed yet. The discrepancies
cited above prompted us to explore whether the Comet and
modified G2 MN assays are able to predict the clinical radiation
reaction of BC patients and to discriminate them from healthy
subjects. In addition, we analysed the influence of previous
radiotherapy (RT) on the radiation response of cells in vitro.W e
examined both baseline and radiation-induced DNA damage in
PBMCs from a much sizeable group of 50 unselected BC patients
compared to that studied before (Djuzenova et al, 1999). PBMCs
from a small group of cancer patients with an adverse early skin
reaction to RT have also been included.
MATERIALS AND METHODS
Subjects
The assay was performed on PBMCs isolated from three groups of
individuals: (1) a group (n¼50) of unselected BC patients who
were prospectively involved in the study and their blood samples
were collected before clinical irradiation; (2) a group of cancer
patients with an adverse early skin reaction (radiation therapy
oncology group (RTOG) grades 2 and 3) to RT, who were
retrospectively involved in the study, hereafter designated as ‘SC,
sensitive cases’ and included seven patients with BC, one with
tongue carcinoma (TC) and one with plasmacytoma (PC). Blood
sampling was carried out during or after cessation of RT; and (3) a
group of apparently healthy donors (n¼16), mainly hospital
personal and their relatives. To our knowledge, none of the healthy
controls was previously exposed to radiation. All patients and
healthy donors were asked to complete a questionnaire on their
medical histories and lifestyles, including genetic diseases,
medication, alcohol consumption, smoking, etc. Patients receiving
chemotherapy prior to RT were excluded. The study was approved
by the University of Wu ¨rzburg Ethics Committee and all patients
and donors gave informed consent.
Radiotherapy treatment of cancer patients was performed by
means of a 6MV linear accelerator (Siemens, Concord, CA, USA)
at a dose rate of 2Gymin
 1. All BC patients received a tangential
irradiation of the whole breast, with lateral and medial wedge
fields. The regimen comprised a total dose of 50 or 60Gy with a
fractionation dose of 2Gy five times a week. The early skin
reaction to RT developing in the skin within the radiation field of
the breast was used as an indicator for clinical radiosensitivity
according RTOG score (Cox et al, 1995).
Blood sampling and isolation of cells
PBMCs were separated from the heparinised blood samples by
density-gradient centrifugation using Ficoll–Histopaque 1077
(Sigma 1077-1, Deisenhofen, Germany) according to the manu-
facturer’s instructions. Peripheral blood mononuclear cells were
washed twice with Ca
2þ- and Mg
2þ-free physiological phosphate-
buffered saline (PBS; Sigma D-8537) and finally resuspended in the
freezing medium containing RPMI 1640 (Sigma R-8758), 10%
foetal calf serum and 10% dimethyl sulphoxide, and stored frozen
in a liquid nitrogen until analysis.
Alkaline Comet assay (slide method)
The Comet assay was performed under alkaline conditions
following a modified protocol initially reported elsewhere (Singh
et al, 1988; Djuzenova et al, 1999, 2001). Fully frosted microscope
slides (SuperFrost Plus
s Menzel GmbH, Braunschweig, Germany)
were dipped up to one-fourth the frosted area in a hot 0.9%
normal-melting-point agarose (Roth, 2268.2; Karlsruhe, Germany)
in PBS. The slides were air-dried and stored at room temperature
until needed. A measure of 80ml of cell/agarose suspension (10ml
of cell suspension containing about 10
4 cells was mixed with 70ml
of 0.6% low-melting-point agarose, Roth, 6351.1, in PBS) was
placed over the first agarose layer and allowed to solidify under a
coverglass. After irradiation, coverglasses were removed, the slides
were gently immersed in a cold lysis solution (2.5 M NaCl, 100mM
ethylenediaminetetraacetic acid (EDTA), 10mM Tris, 1% sodium
sarcosinate, pH was adjusted to 10 with NaOH, 10% dimethyl
sulphoxide and 1% Triton X-100 added just before use) for 1h at
41C to lyse the cells and to permit DNA unfolding. The microscope
slides were then transferred to the horizontal gel electrophoresis
unit filled with fresh, chilled electrophoresis buffer (300mM NaOH,
1m M EDTA, pH 13.5) to a level of about 0.2cm above the slides
and left for 20min to allow unwinding of DNA before electro-
phoresis. Electrophoresis was conducted for the next 20min at
22V (0.83Vcm
 1). The slides were then drained, placed on a tray
and flooded slowly with three changes of a neutralisation buffer
(0.4 M Tris, pH 7.5), each for 5min, to remove alkali. The slides
were then stained with propidium iodide (Sigma P-4170,
10mgml
 1 solution in PBS), 50ml per slide, covered with a
coverglass and placed in a humidified air-tight container to
prevent drying of the gel, and were analysed within 24h.
In vitro X-ray irradiation for comet assay
At 2h prior to irradiation, cells were thawed, centrifuged and
resuspended in 1ml of complete growth medium (CGM),
consisting of RPMI 1640, supplemented with 10% foetal calf
serum, 1% nonessential amino acids, 1mM sodium pyruvate,
2m ML -glutamine and penicillin/streptomycin (100Uml
 1 and
100mgml
 1, respectively). The final cell density of PBMCs was
adjusted to 1 10
6 cellsml
 1 and the samples were placed at 371C
in a 5% CO2 incubator. X-irradiation was performed using a 6MV
Siemens linear accelerator (Siemens, Concord, CA, USA) at a dose
rate of 2Gymin
 1. Cells embedded in agarose were irradiated on
slides on crushed ice and were then placed in ice-cold lysis buffer
(see below) or in CGM at 371C in a water bath for specified times
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sprior to lysis. Nonirradiated cells were treated in similar way (but
at a zero radiation dose).
Comet capture and analysis
Propidium iodide-stained electropherograms were examined in an
epifluorescent microscope (Leica, DMLB, excitation filter: 515–
560nm; barrier filter: 590nm) attached to a black and white CCD
video camera (Cohu Electronics, San Diego, CA, USA), which was
connected to a PC equipped with an image analysis software
Komet 5.5. (Kinetic Imaging Ltd, Liverpool, UK). Between 75 and
100 randomly captured cells from each slide were analysed at each
sampling time. Occasional dead cells, superimposed cells and cells
on the edge of the gels were avoided.
Several features for each cell were evaluated by the software
package, but the ‘tail moment’ (TM) was used here to quantitate
the extent of DNA damage (Olive et al, 1990). The TM value (given
in arbitrary units) is defined as the product of the percentage of
DNA in the comet tail and the tail length. For each cell sample, the
TM data were plotted vs time and fitted to a monoexponential
function:
TMðtÞ¼TM0 exp  
0:693t
t0:5

þ TM0 ð1Þ
where t is the incubation time after X-ray exposure; TM0 and TMR
are the initial repairable TM and residual (i.e. irreparable) TM,
respectively; and t0.5 is the repair half-time, that is, the time
required for cells to restitute 50% of the DNA damage. The total
initial TMI (t¼0) is given by the sum: TMI¼TM0þTMR.
MN test
The MN assay was performed essentially according to Fenech
(1993) with slight modifications. Peripheral blood mononuclear
cells (2–5 10
6ml
 1) were incubated in CGM containing
5mgml
 1 PHA (Sigma L-9132) for 2 days to stimulate the cell
cycle progression. At 1h before irradiation, cytochalasin B
(5mgml
 1, Sigma C-6762) was added to prevent cytokinesis,
which resulted in the appearance of binucleated cells (BNCs). After
irradiation with a single dose of 1, 2, 3 and 4Gy, the cells were
cultured for additional 24h, brought onto glass slides by cytospin
centrifugation, fixed in cold methanol ( 201C, 1h) and finally
stained with acridine orange (62.5mgml
 1, Sigma A-4921) as
described elsewhere (Stopper et al, 2005). The percentage of BNCs
containing MN and the total numbers of MN per a single BNC were
scored in 1000 BNCs using a  400 magnification according the
criteria published elsewhere (Fenech and Morley, 1985a). In the
version of the MN test used here, PBMCs were at first stimulated
with PHA (48h) and then irradiated, so it was a G2 MN test as
compared to the usually performed G0 MN test (Scott et al, 1998;
Baeyens et al, 2002).
Statistics
Data are presented as mean (7s.d.). Mean values were compared
by the Student’s t-test. The threshold of statistical significance was
set at Po0.05. Statistics and fitting of experimental curves were
performed with the program Origin 5.0 (Microcal, Northampton,
MS, USA).
RESULTS
Comet assay
The damage to DNA and its repair kinetics were evaluated up to
40min after exposure to 5Gy of X-rays, with a step of 10min. The
Comet TM (see Materials and Methods) was used to quantify the
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Figure 1 DNA damage assessed by means of the Comet assay in
nonirradiated (A) as well as in irradiated (B–D) PBMCs derived from
unselected BC patients (circles) and radiation-sensitive (unfilled down
triangles) cancer patients compared with the cells from apparently healthy
donors (squares). Initial (B), residual (C) DNA damage and the repair half-
time constants (D) were assessed in PBMCs after irradiation with 5Gy in
vitro. Filled triangles represent the mean values for the respective group.
‘NS’ indicates that the difference was not highly significant (P40.05). To
facilitate visual comparison, the dashed line is drawn through the mean
value of the group of healthy donors. Star and diamond represent the data
for patients 016 and 021 who revealed an adverse skin reaction after RT.
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sextent of DNA damage. The mean TM data were plotted as
functions of time (data not shown) and fitted to equation (1) using
the least-squares method. From the best fits, the values of the
initial (TMI) and residual (TMR) tail moment, as well as the repair
half-time (t0.5) were determined for the cell samples from each
tested individual (Figure 1).
The fitted parameters of DNA damage repair curves for each
individual, as well as the age, sex, clinical and smoking status, are
given in Table 1, from which the following trends are obvious (see
also Figure 1). Although nonirradiated cells of some cancer
patients exhibited noticeably higher baseline amounts of DNA
fragmentation, the mean values of background DNA damage were
similar in the three tested groups of individuals (Figure 1A).
Likewise, after irradiation in vitro, the Comet assay did not reveal
any differences among the three groups in terms of their initial
(Figure 1B) and residual levels of DNA damage (Figure 1C) as well
as in the DNA repair kinetics (Figure 1D), which may be in part
due to the strong interindividual variability.
Out of 50 prospectively recruited BC patients, only two (016 and
021) exhibited an increased early skin reaction to RT (both grades
2 and 3 according RTOG score) so the group of ‘unselected BC’
patients could be also viewed as normally reacting patients.
Table 1 DNA damage measured by the Comet assay in PBMCs isolated from blood of apparently healthy donors (N), unselected BC patients and cancer
patients with adverse skin reaction to RT after exposure to 5Gy of X-irradiation in vitro
a
Subject
b
Age
(years) Sex
Smoking
status
c
Clinical status with
respect to cancer, skin
reaction to RT
d
0Gy, TM
(AU)
Total initial TM,
TMIT (AU)
Residual TM, TMR
(AU)
Repair half-time
(min)
Apparently healthy donors
N-1 26 F — ND 0.44 7.11 0.69 5.81
N-2 27 F — ND 0.38 11.39 2.20 2.23
N-3 39 M — ND 0.60 11.97 0.76 4.51
N-4 30 F — ND 0.48 7.34 0.80 7.39
N-5 51 F — ND 0.57 10.37 0.61 3.80
N-6 32 M 10/day ND 0.69 11.17 0.81 4.40
N-7 31 M — ND 0.37 9.76 0.97 2.64
N-8 25 M — ND 0.44 13.42 0.60 5.74
N-9 24 M — ND 0.26 14.22 0.73 5.08
N-10 27 F — ND 0.45 8.40 0.74 3.89
N-11 25 F — ND 0.43 8.38 1.43 7.63
N-12 62 F — ND 0.74 9.75 1.27 4.26
N-13 49 F — ND 0.48 11.06 1.10 4.84
N-14 67 F — ND 0.36 10.20 1.10 0.48
N-15 66 F — ND 0.61 10.05 0.63 6.05
N-16 77 F — ND 0.59 10.0 1.67 4.78
Mean 41 0.49 10.30 1.0 4.60
7s.d. 18 0.13 2.0 0.45 1.82
BC patients
001 62 F 5–10/day BC, grade 2 0.62 9.82 1.38 4.30
002 63 F — BC, grade 2 1.09 12.34 1.41 6.89
003 68 F — BC, grade 1 0.97 8.61 0.79 4.71
004 65 F — BC, grade 1 0.42 12.74 1.00 5.70
005 58 F — BC, grade 2 0.36 12.52 1.07 4.41
006 79 F — BC, grade 1 0.27 9.71 0.62 4.50
008 64 F — BC, grade 1 0.39 15.05 0.69 6.27
009 47 F 10/day BC, grade 1 0.29 10.14 0.75 10.45
010 75 F — BC, grade 1 0.39 11.01 0.10 13.27
012 58 F — BC, grade 2 0.83 17.96 1.03 3.67
013 55 F — BC, grade 1 0.42 11.99 1.30 4.46
014 73 F — BC, grade 1 0.48 10.81 1.29 2.11
015 72 F — BC, grade 1 0.55 6.36 0.83 7.04
016 66 F — BC, grades 2 and 3 0.71 13.87 1.01 4.04
017 56 F — BC, grade 1 0.23 9.18 0.80 5.28
018 55 F 10–15/day BC, grade 0 and 1 0.36 6.03 0.83 3.46
019 69 F — BC, grade 0 and 1 0.50 6.25 0.26 9.27
020 75 F — BC, grade 0 and 1 0.45 7.40 0.93 5.86
021 69 F — BC, grades 2 and 3 0.32 6.08 0.60 3.23
022 62 F — BC, grade 1 0.27 10.13 0.76 3.87
023 63 F — BC, grade 1 0.45 8.92 1.19 6.60
024 70 F — BC, grade 1 0.34 7.25 1.25 2.77
025 54 F 2–5/day BC, grade 1 0.33 5.90 0.81 4.41
026 74 F — BC, grade 0 0.26 4.78 0.74 4.13
027 38 F — BC, grade 2 0.55 12.36 0.64 8.25
028 59 F — BC, grade 1 0.94 13.81 1.52 9.56
029 67 F — BC, grade 2 0.45 9.89 0.98 5.75
030 63 F — BC, grade 1 0.78 12.65 1.21 4.21
031 47 F 15–20/day BC, grade 1 0.69 14.58 2.63 4.20
032 68 F — BC, grade 0 0.73 14.65 2.37 3.29
033 70 F — BC, grade 1 0.56 8.10 0.66 9.93
034 75 F — BC, grade 1 0.78 8.59 1.0 7.02
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sHowever, only for one of them (Figure 1B, star), the increased
clinical radiosensitivity, correlated with a somewhat higher initial
DNA damage level detected by the Comet assay. Other parameters
of the Comet assay on the cells from these two patients did not
deviate significantly from controls.
MN test
In addition to the Comet assay, the cell samples were analysed by a
cytochalasin-blocked MN test (Fenech and Morley, 1985a) with a
minor modification concerning mitogen stimulation. This test
represents a well-established assay for biomonitoring human
populations as an indicator of genetic instability and radiation
damage (Mu ¨ller et al, 2003). Using the G2 MN test, both percentage
of BNCs with MN (Figures 2, 3, 5) and total numbers of MN per
single BNC (not shown) were scored in a total number of 1000
BNCs. As seen from Figure 2A, there was no difference in the
spontaneous MN yields between unselected BC patients and healthy
controls. In contrast, the PBMCs from cancer patients with an
adverse skin reaction to RT exhibited a significantly higher amounts
of spontaneous MN compared to both control and unselected BC
patients (Figure 2A; Po0.005 and Po0.05, respectively).
In addition to the spontaneous MN formation (Figure 2A), the
induction of MN upon irradiation in vitro with 0–4Gy was
evaluated and the slopes of the dose–response curves were
analysed for each group (Figure 2B). As with the spontaneous MN
levels (Figure 2A), the mean slope of MN induction in cells from
cancer patients with an adverse skin reaction was significantly
higher than in both control and unselected BC group. The latter
two groups exhibited similar dose–response slopes in the G2 MN
test.
In the case of two BC patients (016 and 021) who developed an
increased early skin reaction to RT (Figure 2A, star and diamond),
the mean spontaneous MN yields in their blood cells were similar
to that in control. However, after in vitro irradiation, cells derived
from one of them (patient 021) showed a somewhat higher rate of
MN induction (Figure 2B, diamond).
As an extension of Figure 2B, Figure 3 illustrates the radiation
dose dependences of MN induction averaged through each tested
group of individuals. The dose–response curve of MN induction in
cells from unselected BC patients (Figure 3, circles) is similar to
that obtained for control cells (Figure 3, squares). On the other
hand, cells from cancer patients with an adverse skin reaction to
RT (Figure 3, ‘SC’, triangles) showed significantly higher MN
induction levels compared to controls and unselected BC patients.
As there was an increased amount of spontaneous MN in cells
from radiation-sensitive patients (see also Figure 2A), we
additionally normalised the dose–response data by subtracting
Table 1 (Continued)
Subject
b
Age
(years) Sex
Smoking
status
c
Clinical status with
respect to cancer, skin
reaction to RT
d
0Gy, TM
(AU)
Total initial TM,
TMIT (AU)
Residual TM, TMR
(AU)
Repair half-time
(min)
035 54 F — BC, grade 1 0.41 11.68 1.11 4.45
036 48 F — BC, grade 1 0.31 9.27 1.07 3.17
037 58 F — BC, grade 1 0.34 6.26 0.65 4.09
038 75 F 2–5/day BC, grade 1 0.37 11.21 1.32 3.38
039 60 F — BC, grade 2 0.47 13.26 1.21 4.30
040 54 F — BC, grade 2 0.67 12.7 1.45 4.52
041 45 F — BC, grade 1 0.41 12.53 1.35 4.40
042 57 F — BC, grade 1 0.66 10.61 0.88 6.33
043 41 F — BC, grade 2 0.33 8.05 0.89 3.76
044 67 F — BC, grade 1 0.65 11.1 0.87 2.99
045 61 F — BC, grades 0 and 1 0.31 13.07 1.09 6.22
046 69 F — BC, grade 1 0.27 9.19 0.43 7.31
047 55 F 6–8/day BC, grade 2 0.34 7.93 0.48 6.10
048 61 F — BC, grade 2 0.64 15.18 1.52 7.02
049 71 F — BC, grade 1 0.51 10.17 0.81 5.47
050 60 F 20/day BC, grade 1 0.40 8.96 1.13 3.94
051 43 F 2–3/day BC, grade 2 0.39 9.26 1.02 3.26
052 56 F — BC, grade 1 0.31 15.43 1.02 5.42
Mean 61 0.49 10.50 1.02 5.38
7s.d. 10 0.20 3.0 0.43 2.23
NS NS NS
Cancer patients with adverse skin reaction to RT
SC1 43 F — BC, grades 2 and 3 0.29 8.52 0.73 7.20
SC2 50 M — TC, grades 2 and 3 2.18 9.71 1.77 5.51
SC3 49 F 5–10/day BC, grades 2 and 3 1.0 9.15 0.79 10.09
SC4 49 M — BC, grades 2 and 3 0.51 7.74 1.13 5.29
SC5 64 M — PC, grades 2 and 3 0.31 10.77 1.16 2.17
SC6 52 F 2–5/day BC, grade 3 0.61 6.87 1.01 5.50
SC7 49 F — BC, grades 2 and 3 0.29 12.08 0.74 5.40
SC8 63 F — BC, grades 2 and 3 0.59 7.02 1.28 2.74
SC9 69 F — BC, grades 2 and 3 0.36 16.92 1.38 2.35
Mean 54 0.68 9.9 1.1 5.14
7s.d. 9 0.61 3.2 0.3 2.53
BC¼breast cancer; F¼female; M¼male; N¼normal; ND¼not determined; PBMC¼peripheral blood mononuclear cells; PC¼plasmacytoma; RT¼radiotherapy;
SC¼sensitive case; TC¼tongue carcinoma.
aEach indicated DNA damage parameter represents the mean value obtained on the cells from a given individual. Significance was
established using Student’s t-test. P compares the differences between tested group and apparently healthy individuals. NS indicates that the difference was not highly significant
(P40.05). Bold fonts indicate the unselected BC patients who revealed an adverse skin reaction to RT.
bCase number was according to our files.
c‘—’ means nonsmoker, the
numbers indicate the amounts of smoked cigarettes per day.
dEarly skin reaction according RTOG score (Cox et al, 1995). RTOG grade: 1 – follicular, faint or dull erythema, dry
desquamation; 2 – tender or bright erythema, moderate oedema; 3 – confluent, moist desquamation, pitting oedema; 4 – ulceration, haemorrhage, necrosis.
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sthe background MN levels (Figure 3, inset). In the normalised plot,
cells from radiation-sensitive cancer patients exhibited the highest
relative rate of MN induction in vitro, whereas the dose–response
of cells from unselected BC patients was similar to that of control
group.
Effects of previous RT on the radiation response of
patients’ cells in vitro
As mentioned above, blood samples of cancer patients with an
adverse skin reaction to RT (group 2 in Materials and Methods)
were collected during or after clinical irradiation. In order to
investigate the influence of previous RT on the radiation response
of patients’ cells in vitro, blood samples from five unselected BC
patients were taken before, during (at 20 and 40Gy) and after (50–
60Gy of cumulative RT dose) clinical irradiation and analysed by
the Comet and MN assays. The Comet assay applied after 5Gy in
vitro revealed that the initial DNA fragmentation rose with
increasing cumulative dose of RT in cells of four out of five tested
patients (Figure 4A). Unlike the initial DNA damage, no
conclusions could be drawn about the influence of previous RT
on the residual DNA damage and repair half-time (Figure 4B and
C, respectively), mainly because of the wide individual variability
of these parameters. In addition, the background DNA damage
level (i.e. tail moment at 0Gy in vitro) remained unchanged after
clinical irradiation (data not shown).
The G2 MN assay of the same cell probes shown in Figure 4
revealed that previous RT exerted strong effects on both baseline
and in vitro radiation induced MN yields (Figure 5). Thus, for a
given radiation dose in vitro (0–4Gy), the mean MN frequencies
grew steadily with increasing cumulative RT dose for all five tested
BC patients (Figure 5A–E).
DISCUSSION
In this study, peripheral blood cells isolated from (1) unselected
BC patients, (2) cancer patients with an adverse early skin reaction
to RT, and (3) healthy individuals were analysed for their DNA
fragmentation using the Comet assay. The analysis of both
nonirradiated and in vitro-irradiated cell samples did not reveal
any differences in the background or radiation-induced DNA
damage levels among the three groups. There was a trend toward
an increased background level in the cells from both groups of
cancer patients, but this failed to reach statistical significance. The
Comet data obtained here are in agreement with the findings that
the baseline DNA damage levels in nonirradiated peripheral blood
lymphocytes from patients with multiple tumours (Mu ¨ller-Vogt
et al, 2003), lung cancer (Rajaee-Behbahani et al, 2001) and breast
cancer (Alapetite et al, 1999) are similar to healthy controls. Our
results, although without accounting for BRCA1 and BRCA2
mutations, but on a sizeable sample (n¼50) of unselected BC
patients, are also in line with the finding of Rothfuß et al (2000)
that the Comet assay has not revealed any difference between the
in vitro-irradiated cells from four patients with BRCA1 mutation
and those from four control subjects.
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Figure 2 Spontaneous MN expression (A) and the slopes (B) of the
dose–response curves for MN induction after in vitro irradiation with
0–4Gy in PBMCs derived from unselected (circles) and sensitive (unfilled
down triangles) cancer patients are shown in comparison with those in the
cells from control subjects (squares). Each data point in (A) represents the
mean frequency of micronucleated BNCs scored in 1000 BNCs. Each data
point in (B) represents the slope of the dose–response curve for MN
induction in 1000 BNCs (per a single dose of radiation) from a given
individual. Filled triangles represent the mean values for the respective
group. ‘NS’ indicates that the difference was not highly significant (P40.05).
To facilitate visual comparison, the dashed line is drawn through the mean
value of the group of healthy donors. Star and diamond represent the data
for patients 016 and 021 who revealed an adverse skin reaction after RT.
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Figure 3 Spontaneous and radiation-induced MN expression in PBMCs
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Durel et al (2004) and Hussien et al (2005), who have found
increased levels of both basal and radiation-induced DNA damage
in cells from BC patients, as compared to healthy controls. The
reasons for the discrepancy might reside in the patients’ and
controls’ cohorts, cancer stage, treatment prior to blood sampling,
arbitrary determined cut off values, experimental protocols as well
as in interlaboratory variability. Thus, in contrast to the present
and several other studies (Alapetite et al, 1999; Rothfuß et al, 2000;
Mu ¨ller-Vogt et al, 2003), in which healthy individuals were used as
references, the control group in Hussien et al (2005) includes
patients with the benign breast disease. Besides this, even if the
same version of the alkaline Comet assay (Singh et al, 1988) was
used here and elsewhere (Colleu-Durel et al, 2004; Hussien et al,
2005), the quantitative TM data appear to differ greatly between
laboratories. Thus, the TM values of 7.74 and 14.67 in
nonirradiated cells from control and BC patients, respectively,
obtained by Colleu-Durel et al (2004) are larger some 20–30-fold
than the TM values of 0.47 and 0.45 presented here in Figure 1A.
For comparison, the TM values of 1.4 and 1.21 have been found,
respectively, for bladder cancer patients and controls (Schabath
et al, 2003), whereas TM values of about three have been obtained
for both breast cancer patients and controls by Alapetite et al
(1999).
The second screening test used here was the MN assay. Unlike
the usual version of the MN test, which involves irradiation of
quiescent G0 cells followed by mitogen stimulation (Scott et al,
1998; Burrill et al, 2000; Baeyens et al, 2002), in the present study,
the cells were stimulated with PHA for 48h prior to irradiation, as
commonly used for assessing G2 chromosomal aberrations (Scott
et al, 1998). We found that the mean frequencies of both
spontaneous and radiation-induced MN in PBMCs from unse-
lected BC patients were similar to those in control. Consistent with
the G2 MN data presented here, the G0 MN assay also has failed to
discriminate a group of cervical, head and neck cancer patients
from healthy individuals (Slonina et al, 2000). In addition, the
radiomimetic drug bleomycin induces similar rates of chromatid
breaks in lymphocytes from BC patients and from healthy controls
(Hsu et al, 1989).
On the other hand, the data for the group of unselected BC
patients obtained here using the G2 MN test seem to disagree with
those from several studies (Scott et al, 1998; Burrill et al, 2000;
Baeyens et al, 2002), in which the G0 MN test has detected
increased radiosensitivity in cells from BC patients compared to
healthy controls (reviewed in Speit and Trenz, 2004). The apparent
conflict, however, can be explained by differences in both
experimental and statistical approaches used here and elsewhere
(Scott et al, 1998; Burrill et al, 2000; Baeyens et al, 2002). Firstly, we
used a modified G2 version of the MN test instead of the classic G0
MN assay. Secondly, we compared the mean values of groups
rather than the data ranges. Thirdly, we did not set any arbitrary
cut off values. Finally, the control and patients’ cohorts differ
markedly among studies.
We also found that blood cells from cancer patients with an
adverse early skin reaction to RT displayed increased frequencies
of both spontaneous and radiation-induced MN compared to the
cells from apparently healthy donors and unselected BC patients
(Figures 2 and 3). This result is in agreement with the findings that
MN levels are elevated in cells from BC patients with known
genetic predisposition (Rothfuß et al, 2000; Baeyens et al, 2002). It
has to be noted, however, that in our study the radiation-sensitive
cancer patients were recruited based on the knowledge of their
clinical reaction to RT, so that blood sampling was performed
during or after cessation of RT. This fact raised an important
question whether RT itself affects the outcome of in vitro tests. To
check this possibility, we further analysed blood samples (of five
patients) collected prior, during (20 and 40Gy) and after (50–
60Gy) cessation of RT. A striking effect of the radiation in vivo on
the spontaneous and radiation-induced MN yields in vitro was
observed in all five tested patients (Figure 5). These data suggest
that clinical radiation might have provoked genetic instability and/
or induced persistent (nonrepaired) DNA damage in the normal
cells of cancer patients, thus leading to increased levels of MN
induction and DNA fragmentation after irradiation in vitro. Our
data agree with the observations that MN levels rise with
increasing cumulative RT dose in cancer patients (Fenech et al,
1990; Cao et al, 2002), although some studies report a lack of
difference in the G2 chromosomal radiosensitivity between pre-
and post-therapy samples (Roberts et al, 1999; Baeyens et al, 2002).
Furthermore, the increased frequency of spontaneous MN in cells
from BC patients has been suggested to be caused, at least partly,
by previous radio- and/or chemotherapy (Baeyens et al, 2002),
which is in agreement with our data presented in Figure 5.
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Figure 4 Effects of foregoing RT on the radiation response in vitro of
cells from five breast cancer patients (017, 018, 019, 020 and 022, see
Table 1) with normal clinical radiosensitivity assessed by the Comet assay.
(A–C) The initial and the residual DNA damage, and the repair half-time
constants, respectively. Data were averaged through 75 cells from a given
individual per dose and time point. Blood samples were collected before,
during (20 and 40Gy) and after cessation (50–60Gy) of RT. Bars for the
means have been omitted for clarity.
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sUnlike the MN test, the Comet assay revealed only a weak
correlation between the initial DNA damage and cumulative RT
doses (Figure 4A), whereas other parameters, including the
residual DNA damage and repair half-time constants, do not allow
any conclusions to be made, mainly because of the wide data
scattering. In addition, the Comet assay did not detect any changes
in the background DNA fragmentation in peripheral lymphocytes
from BC patients subjected to RT (data not shown).
It may be argued that in the present study the small control
group (an average age of 41718 years) was much younger than
each tested patients’ group (mean age of 61710 and 5579).
However, it has been shown earlier that while the basal levels of
DNA damage in the Comet assay are independent of the age of the
donor, an age-dependent increase in DNA damage has been
observed immediately after irradiation (Singh et al, 1990). In
addition, a nearly four-fold increase in MN in cultures from 80-
year-old donors was measured compared with that in the cultures
from newborn donors (Fenech and Morley, 1985b), and an age
dependent increase of 0.58MNyear
 1 was found for a female
population (Thierens et al, 2000). Taking these data into account,
the cells from the much elderly group of BC patients studied here
could be expected to exhibit increased levels of both radiation-
induced DNA damage and spontaneous MN expression, as
compared with those from the younger controls. However, at
variance with expectation, there was no significant difference in
the induced DNA damage between the group of unselected BC
patients and controls (Figures 1 and 2). Likewise, the two groups
exhibited similar baseline frequencies of MN expression
(Figure 2A). Another point is that our control group includes
several males, whereas BC patients’ groups include only females.
However, the effect of gender on the outcome of both Comet and
MN tests has been reported to be negligible (Garaj-Vrhovac and
Kopjar 2003; Hadjidekova et al, 2003).
As fortunately a minority (about 5%) of RT patients develop
during or after RT either acute or late radiotoxic responses
(Norman et al, 1988), a cohort of 50 prospectively recruited BC
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Figure 5 Effects of foregoing RT on the MN induction in vitro in cells from five breast cancer patients with normal clinical radiosensitivity. Blood samples
were collected before, during (20 and 40Gy) and after cessation (50–60Gy) of RT. Each symbol represents the mean numbers of BNCs containing MN
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spatients in our study was too small to find several
radiation-sensitive patients. Indeed, we observed only two patients
exhibiting early skin radiotoxicity during or shortly after RT.
Even so, there was a weak correlation of radiation response
in vivo with either an increased DNA damage level in Comet assay
or an increased MN induction in one or another case.
Furthermore, the present study is ongoing, so that potential late
effects of RT are still to be analysed and they will be the subject of
future follow-up.
In conclusion, neither prospectively recruited BC patients
nor sensitive cancer patients with an adverse skin reaction to
RT could be identified by the Comet assay. In contrast, the
modified G2 MN test detected significantly increased levels of
both spontaneous and radiation-induced MN in cells from
sensitive cancer patients. However, the G2 MN assay was unable
to identify normally reacting BC patients. The increased MN
rates in sensitive cancer patients might have been in part a
consequence of the previous RT, which was found to affect
strongly the outcome of the MN test in vitro. A larger study is
required to investigate to what extent RT alters the radiation
response of patients’ cells in vitro.
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